270 related articles for article (PubMed ID: 6486830)
1. [Estracyt (estradiol-nitrogen mustard complex)--estramustine binding protein and its specificity].
Yamanaka H; Imai K; Suzuki T; Yuasa H; Takahashi E
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2106-14. PubMed ID: 6486830
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
3. Partial characterization and "quantitation" of a human prostatic estramustine-binding protein.
Björk P; Forsgren B; Gustafsson JA; Pousette A; Högberg B
Cancer Res; 1982 May; 42(5):1935-42. PubMed ID: 7066904
[TBL] [Abstract][Full Text] [Related]
4. Binding characteristics of a major protein in rat ventral prostate cytosol that interacts with estramustine, a nitrogen mustard derivative of 17 beta-estradiol.
Forsgren B; Gustafsson JA; Pousette A; Högberg B
Cancer Res; 1979 Dec; 39(12):5155-64. PubMed ID: 40694
[TBL] [Abstract][Full Text] [Related]
5. The presence in rat and human prostate of proteins that bind steroid-cytostatic complexes.
Forsgren B; Björk P; Carlström K; Gustafsson JA; Pousette A; Högberg B
Prog Clin Biol Res; 1981; 75A():391-407. PubMed ID: 7339627
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of retention of estramustine in the rat prostate and results of a clinical trial of Estracyt in Japan.
Yamanaka H; Imai K; Yuasa H; Shida K
Prostate; 1981; Suppl 1():95-102. PubMed ID: 7043423
[TBL] [Abstract][Full Text] [Related]
7. Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue.
Walz PH; Björk P; Gunnarsson PO; Edman K; Hartley-Asp B
Clin Cancer Res; 1998 Sep; 4(9):2079-84. PubMed ID: 9748122
[TBL] [Abstract][Full Text] [Related]
8. The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer.
Forshell GP; Müntzing J; Ek A; Lindstedt E; Dencker H
Invest Urol; 1976 Sep; 14(2):128-31. PubMed ID: 972005
[TBL] [Abstract][Full Text] [Related]
9. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
10. Estramustine-binding protein in rat and human prostate.
Forsgren B
Scand J Urol Nephrol Suppl; 1988; 107():56-8. PubMed ID: 3287598
[TBL] [Abstract][Full Text] [Related]
11. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
Norlén BJ; Andersson SB; Björk P; Gunnarsson PO; Fritjofsson A
J Urol; 1988 Nov; 140(5):1058-62. PubMed ID: 3172360
[TBL] [Abstract][Full Text] [Related]
12. Binding of estramustine, a nitrogen mustard derivative of estradiol-17 beta, in cytosol from rat ventral prostate.
Forsgren B; Högberg B; Gustafsson JA; Pousette A
Acta Pharm Suec; 1978; 15(1):23-32. PubMed ID: 645366
[No Abstract] [Full Text] [Related]
13. Expression of an estramustine-binding associated protein in human lung cancer cell lines.
Bergh J; Björk P; Westlin JE; Nilsson S
Cancer Res; 1988 Aug; 48(16):4615-9. PubMed ID: 2840198
[TBL] [Abstract][Full Text] [Related]
14. Studies on the estramustine-binding protein in rat ventral prostate and in human prostate.
Gustafsson JA; Björk P; Carlström K; Forsgren B; Hökfelt T; Pousette A; Högberg B
Scand J Urol Nephrol Suppl; 1980; 55():133-4. PubMed ID: 6163205
[No Abstract] [Full Text] [Related]
15. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.
Gunnarsson PO; Andersson SB; Johansson SA; Nilsson T; Plym-Forshell G
Eur J Clin Pharmacol; 1984; 26(1):113-9. PubMed ID: 6714283
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
[TBL] [Abstract][Full Text] [Related]
18. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
Edsmyr F; Esposti PL; Andersson L
Scand J Urol Nephrol Suppl; 1980; 55():139-42. PubMed ID: 6938017
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
20. Binding sites for the cytotoxic metabolites of estramustine phosphate (Estracyt) in rat and human pancreas that are distinct from pancreatic estrogen-binding protein.
Björk P; Jönsson U; Andrén-Sandberg A
Pancreas; 1991 Jan; 6(1):77-89. PubMed ID: 1994382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
